Skip to Content

Join the 'Osteolytic Bone Metastases of Breast Cancer' group to help and get support from people like you.

Osteolytic Bone Metastases of Breast Cancer News

Related terms: Bone Metastases of Breast Cancer

Exercise a Powerful Ally for Breast Cancer Survivors

Posted 21 Feb 2017 by Drugs.com

TUESDAY, Feb. 21, 2017 – For breast cancer survivors, exercise may help lower their chances of dying from the disease more than other healthy habits, a new review suggests. The Canadian researchers analyzed 67 published articles to see which habits made the most difference in reducing the risk of either breast cancer recurrence or death. Exercise came out on top, reducing the risk of breast cancer death by about 40 percent, said review author Dr. Ellen Warner, a medical oncologist at Sunnybrook Odette Cancer Centre and a professor at the University of Toronto. "It's similar to the magnitude of chemotherapy or hormone therapy," she said. "So, that's pretty powerful." However, the review did not prove that exercise causes breast cancer risk to drop. Besides exercise, the previous research looked at weight and weight gain, diet, smoking, alcohol and vitamin supplements. The new review ... Read more

Related support groups: Obesity, Weight Loss, Breast Cancer, Vitamin/Mineral Supplementation and Deficiency, Vitamin C, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Caltrate 600 with D, Breast Cancer - Palliative, Ascorbic Acid, Citracal + D, Calcium/Vitamin D, Citracal Petites, Ester-C, Osteolytic Bone Metastases of Breast Cancer, Cecon, Protexin, Oysco 500 with D, Oyster Shell Calcium

Many Women Skip Mammograms After False-Positive Result

Posted 9 Feb 2017 by Drugs.com

THURSDAY, Feb. 9, 2017 – The trauma of receiving a false-positive result from a mammogram may lead many women to delay or skip their next screening, a new study finds. A false-positive result means that an aberration on a mammogram looks like it might be cancer. But after tests – such as added imaging or biopsy – it turns out to be benign. In the meantime, however, the patient may go through distress and various procedures, and decide to delay or skip her next mammogram. That's a potentially fatal mistake, breast cancer experts said, because detecting tumors early can save lives. "Unfortunately, for women over age 50, just skipping a mammogram every other year would miss up to 30 percent of cancers," said Dr. Stefanie Zalasin, a breast imaging specialist who reviewed the new findings. "Reassuring a patient that the overwhelming majority of mammograms and even biopsies are normal can ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Osteolytic Bone Metastases of Breast Cancer, Body Imaging

Too Few High-Risk Women Tested for Breast Cancer Gene: Survey

Posted 7 Feb 2017 by Drugs.com

TUESDAY, Feb. 7, 2017 – Though testing for two genes that raise breast cancer risk has been around for decades, a new survey finds many high-risk women don't get the test, often because they aren't told to by their doctors. Among women with the highest risk, about eight of 10 said they wanted testing for the BRCA1 and BRCA2 mutations. But, "only about half of them actually got the testing they should get," said study author Dr. Allison Kurian, from Stanford University's School of Medicine. "Genetic cancer testing is not well matched to the medical needs of the patient, to a woman's risk of having a mutation," said Kurian, an associate professor of medicine and of health research and policy. Why the gap? About 56 percent of the high-risk women who were not tested said their doctors did not recommend it, the survey found. In addition to the test itself, genetic counseling can help ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Ovarian Cancer, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Osteolytic Bone Metastases of Breast Cancer

Half Report Severe Side Effects From Breast Cancer Therapy

Posted 24 Jan 2017 by Drugs.com

TUESDAY, Jan. 24, 2017 – About half of early stage breast cancer patients experience severe side effects from their treatment, a new study finds. "It's in patients' best interest to receive their treatments on time and on schedule, whenever possible, to give them the best possible outcome," said study author Dr. Steven Katz. He's professor of health management and policy at the University of Michigan. "Unscheduled care for toxicities [side effects] – including clinic visits, emergency department visits and hospital stays – are expensive, inconvenient and disruptive to both doctors and patients. We need to avoid them whenever possible," Katz said in a university news release. For the study, researchers surveyed almost 2,000 early stage breast cancer patients an average of seven months after diagnosis. The women were asked to rate the severity of seven common treatment side effects: ... Read more

Related support groups: Surgery, Breast Cancer, Fluorouracil, Efudex, Carac, Breast Cancer, Metastatic, Herceptin, Taxol, Breast Cancer - Adjuvant, Taxotere, Carboplatin, Cytoxan, Cyclophosphamide, Paclitaxel, Breast Cancer, Prevention, Fluoroplex, Doxorubicin, Adriamycin, Breast Cancer - Palliative, Docetaxel

Study Casts More Doubt on Value of Mammograms

Posted 10 Jan 2017 by Drugs.com

MONDAY, Jan. 9, 2017 – Mammograms frequently detect small breast tumors that might never become life-threatening, causing women to receive treatment they likely don't need, a new Danish study finds. About one in every three women between the ages of 50 and 69 who was diagnosed with breast cancer wound up having a tumor that posed no immediate threat to her health, the researchers reported. At the same time, mammography did not reduce the number of advanced breast cancers found in women in the study. "This means that breast screening is unlikely to improve breast cancer survival or reduce the use of invasive surgery," said study author Dr. Karsten Juhl Jorgensen, deputy director of research for the Nordic Cochrane Center at the Rigshospitalet in Copenhagen. "It also means that breast screening leads to unnecessary detection and treatment of many breast cancers." Dr. Otis Brawley, chief ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Anastrozole, Zoladex, Evista, Letrozole, Megestrol, Megace, Herceptin, Aromasin, Exemestane, Casodex, Eligard

Many With Breast Cancer Unnecessarily Choose Double Mastectomy: Study

Posted 22 Dec 2016 by Drugs.com

WEDNESDAY, Dec. 21, 2016 – Many women with early stage breast cancer choose to have their healthy opposite breast removed, even when there are no medical indications that such a step is necessary, a new survey finds. That's especially true when the surgeon doesn't offer a recommendation either way, the researchers said. "We are seeing that one in six breast cancer patients are choosing bilateral mastectomy when this aggressive procedure is not going to benefit them in terms of survival," said Dr. Reshma Jagsi. Jagsi, who led the study, is a professor and deputy chair of radiation oncology at the University of Michigan School of Medicine. Cancer specialists say no compelling evidence suggests a survival advantage for most patients to chose a double mastectomy. Also, the risk of getting cancer in the opposite healthy breast is low for most patients, they note. However, after actress ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Minority Women Less Likely to Get Breast Cancer Screening

Posted 16 Dec 2016 by Drugs.com

FRIDAY, Dec. 16, 2016 – Black and Hispanic women are less likely than white women to be screened for breast cancer, a large review finds. Screening rates for Asian/Pacific Islander and white women were similar, the research showed. The analysis of 39 studies including 6 million women was published Dec. 16 in the Journal of the American College of Radiology. "Not only do black and Hispanic women get screened less than white women, but disparities also persist in two age groups: women who are 40 to 65 years old, and 65 and older," study author Dr. Ahmed Ahmed said in a journal news release. "These findings are important; it's evident that more work needs to be done to ensure that all eligible women have access to this preventive screening tool," added Ahmed. He's a postdoctoral fellow researcher at the Mayo Clinic in Rochester, Minn. A great deal of effort has gone into finding racially ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Body Imaging

Beating Breast Cancer But Still Paying a Price

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – Women who survive breast cancer often experience lingering physical and emotional symptoms that go untreated, new research suggests. Ninety-two percent of long-term breast cancer survivors report at least three untreated symptoms for which they need assistance, according to the study. The most common unmet needs are achy joints, fatigue and weight gain – each affecting about one in four survivors in the study. Survivors living with more unmet needs are also more likely to experience anxiety and depression, the study found. Although the study involved just over 100 mostly white and college-educated women at one cancer center, the findings may be important for the nation's 2.8 million breast cancer survivors, the study authors suggest. When you extrapolate these results to the larger population of survivors, "it gets a lot worse very quickly," said lead author ... Read more

Related support groups: Anxiety and Stress, Breast Cancer, Psychiatric Disorders, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Breast Cancer Death Rates Vary Around the World

Posted 11 Dec 2016 by Drugs.com

FRIDAY, Dec. 9, 2016 – Breast cancer death rates are falling in the United States and many other countries, but increasing in South Korea and some Latin American countries, researchers report. The investigators looked at data from 47 countries from 1987 to 2013. They found that breast cancer death rates declined in 39 of those nations due to advances in detection and treatment over the past few decades. The largest decrease was in England and Wales, with a 46 percent drop. In the United States, the breast cancer death rate fell 42 percent. It dropped from 22 deaths per 100,000 women in 1987-1989 to 14 deaths per 100,000 women in 2011-2013, the study showed. Rates declined in all age groups in the United States: by 50 percent for women under 50; by 44 percent for women between 50 and 69; and by 31 percent for women 70 or older. There were mixed findings from Latin America. For example, ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Tamoxifen May Get Blamed for Unrelated Symptoms

Posted 9 Dec 2016 by Drugs.com

FRIDAY, Dec. 9, 2016 – Some high-risk women who take tamoxifen to prevent breast cancer may mistake naturally occurring nausea and vomiting for side effects of the drug and stop taking it, a new study finds. Previous research has shown that taking tamoxifen can reduce the risk of breast cancer by more than 30 percent in high-risk women, and the preventive effects last more than 20 years, the study authors said. But a study of women taking tamoxifen in the United Kingdom found that one-third didn't continue the treatment for the recommended five years. Those who experienced nausea and vomiting were more likely to stop taking the drug than those without such symptoms, the findings showed. However, women who were taking an inactive placebo and had the same symptoms were equally likely to stop. That suggests that some symptoms triggered by other causes were being mistaken for side effects ... Read more

Related support groups: Breast Cancer, Tamoxifen, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Tamoxifen Hexal, Nolvadex, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Emblon

Could a Computer Someday Guide Breast Cancer Care?

Posted 9 Dec 2016 by Drugs.com

FRIDAY, Dec. 9, 2016 – An artificially intelligent computer system is making breast cancer treatment recommendations on a par with those of cancer doctors, a new study reports. The IBM computer system – called Watson Oncology – made treatment recommendations that jibed nine out of 10 times with those of a multidisciplinary board of doctors at a top cancer hospital in India, researchers say. In cases involving more complex cancers, however, the computer did not hit that 90 percent mark. Another version of Watson famously defeated two former winners on the game show "Jeopardy!" in 2011, winning a first-place prize of $1 million. In its oncology role, Watson digests a patient's medical history and current cancer data in under a minute. It then spends another minute reviewing all existing medical evidence regarding their particular form of cancer, said study co-author Dr. S.P. ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Breast Cancer - Male, Osteolytic Bone Metastases of Breast Cancer

Certain Breast Cancer Drugs Tied to Blood Vessel Damage

Posted 9 Dec 2016 by Drugs.com

FRIDAY, Dec. 9, 2016 – Women on breast cancer drugs called aromatase inhibitors may show signs of early blood vessel damage that could lead to heart disease, a small study suggests. Researchers found that compared with healthy women their age, women on aromatase inhibitors were more likely to show signs of "endothelial dysfunction." That refers to problems in how the blood vessel lining responds to blood flow. The findings are based on just 36 women who were prescribed the drugs. And experts stressed it's too early to know what to make of the results. Still, the study adds to evidence linking aromatase inhibitors to elevated risks of high blood pressure, high cholesterol and possibly full-blown heart disease. Aromatase inhibitors include the drugs Aromasin (exemestane), Arimidex (anastrozole) and Femara (letrozole). These drugs work by lowering a woman's estrogen levels, and are often ... Read more

Related support groups: Heart Disease, Breast Cancer, Arimidex, Femara, Anastrozole, Breast Cancer, Metastatic, Letrozole, Aromasin, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Infectious Heart Disease, Teslac, Testolactone

New Drug Combo Shows Promise Curbing Tough-to-Treat Breast Cancer

Posted 8 Dec 2016 by Drugs.com

THURSDAY, Dec. 8, 2016 – In women with a certain form of tough-to-treat breast cancer, treatment with a combination of two drugs appeared to keep the cancer at bay longer – from about five months to 10, a new study says. The cancer is known as "advanced hormone receptor positive, HER 2 negative" breast cancer. Women with these tumors are often given drugs called aromatase inhibitors, which work by reducing estrogen in the body and slowing the growth of the cancer. However, patients commonly develop resistance to aromatase inhibitor drugs, and they stop working. This is also known as endocrine therapy resistance. The new research may offer these patients some hope, researchers said. "Our study has shown that combining a newer medicine called everolimus [Afinitor] with a more established medicine, fulvestrant [Faslodex], has demonstrated benefit in aromatase inhibitor resistant breast ... Read more

Related support groups: Breast Cancer, Estradiol, Premarin, Ethinyl Estradiol, Estrace, Arimidex, Femara, Vagifem, Estrace Vaginal Cream, Vivelle, Anastrozole, Breast Cancer, Metastatic, Climara, Letrozole, Estring, Premarin Vaginal, Vivelle-Dot, Estradiol Patch, Aromasin, Afinitor

Taking Breast Cancer Prevention Drug Beyond 5 Years May Not Raise Survival

Posted 7 Dec 2016 by Drugs.com

WEDNESDAY, Dec. 7, 2016 – Many breast cancer survivors take anti-estrogen drugs for at least five years to help lessen their risk of recurrence. Now, new research suggests that taking such a drug for an even longer period might not confer any added benefit – at least in terms of survival. The study of thousands of older breast cancer survivors found that taking the aromatase inhibitor drug letrozole (Femara) for more than the recommended five years did not help them live longer. However, other benefits were noted, so the decision to extend use of drugs like these is one best made on a case-by-case basis, cancer specialists said. One oncologist who reviewed the new findings said the study has been "eagerly awaited," since many breast cancer survivors are counseled to take an aromatase inhibitor. "For now, this trial reinforces the need to listen to our patients and weigh out the risk ... Read more

Related support groups: Breast Cancer, Arimidex, Femara, Anastrozole, Breast Cancer, Metastatic, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Breast Cancer - Male, Osteolytic Bone Metastases of Breast Cancer, Teslac, Testolactone

New Drug May Brighten Outlook for Advanced Breast Cancer

Posted 16 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 16, 2016 – A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year for treating advanced cases of ER-positive breast cancer. That means the cancer uses the hormone estrogen to help fuel its growth. The approval was based on an earlier-stage study where the drug, used along with a standard drug called letrozole (Femara), helped keep women's cancer at bay. Palbociclib doubled the time patients remained progression-free compared to letrozole alone. The new findings, published in the Nov. 17 New England Journal of Medicine, confirm the earlier results in a larger group of women. "We found that the degree of clinical benefit was, again, remarkable," said lead researcher Dr. Richard Finn, an assistant professor of medicine at the ... Read more

Related support groups: Breast Cancer, Femara, Breast Cancer, Metastatic, Letrozole, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Ibrance, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Palbociclib

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer

Related Drug Support Groups

pamidronate, Aredia